SR Pharma plc Announces Start of Phase I trial with Novel RNAi Therapeutic RTP-801i in Age- related Macular Degeneration (AMD)
07 Feb 2007 -
SR Pharma plc announced that Quark Biotech Inc. has started a Phase I clinical trial with RTP-801i, a small interfering RNA (siRNA) therapeutic product licensed from Atugen AG, a subsidiary of SR Pharma plc. RTP-801i is based on Atugen's proprietary siRNA (AtuRNAi) technology and modifies the expression or function of one specific gene target, which is involved in the progression of Age-related Macular
Degeneration (AMD). RTP-801i has been licensed to Quark Biotech for the treatment of AMD and other diseases. This Phase I study is being funded by Pfizer Inc., which in-licensed RTP-801i for the treatment of AMD.
Top
Contact
Print version
PDF version
Send article
RSS-Feed